583 related articles for article (PubMed ID: 14700163)
1. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
4. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin failure and retreatment in Kawasaki disease.
Durongpisitkul K; Soongswang J; Laohaprasitiporn D; Nana A; Prachuabmoh C; Kangkagate C
Pediatr Cardiol; 2003; 24(2):145-8. PubMed ID: 12457253
[TBL] [Abstract][Full Text] [Related]
6. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
7. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
8. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
9. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
Sittiwangkul R; Pongprot Y; Silvilairat S; Phornphutkul C
Singapore Med J; 2006 Sep; 47(9):780-4. PubMed ID: 16924360
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C; Yeung RS; Chahal N; McCrindle BW
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[TBL] [Abstract][Full Text] [Related]
11. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
Tsai MH; Huang YC; Yen MH; Li CC; Chiu CH; Lin PY; Lin TY; Chang LY
J Pediatr; 2006 Jan; 148(1):38-43. PubMed ID: 16423595
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G; Masi L; Giani T; Piscitelli E; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
14. Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000).
Lee KY; Han JW; Lee HS; Hong JH; Hahn SH; Lee JS; Whang KT
Pediatr Infect Dis J; 2004 Jan; 23(1):52-5. PubMed ID: 14743047
[TBL] [Abstract][Full Text] [Related]
15. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S; Safari M; Amin R
Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
[TBL] [Abstract][Full Text] [Related]
16. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
17. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Yang KD; Liang CD; Bong CN; Yu HR; Wang L; Wang CL
Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
[TBL] [Abstract][Full Text] [Related]
18. A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease.
Arj-ong S; Chotivitayatarakorn P; Lertsapcharoen P; Khongphatthanayothin A; Thisyakorn C
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S179-88. PubMed ID: 12929987
[TBL] [Abstract][Full Text] [Related]
19. Kawasaki disease in central area of Northeast Thailand.
Panamonta M; Chaikitpinyo A; Durongpisitkul K; Somchit S; Petcharatana S; Wongswadiwat Y; Kosalaraksa P; Lumbiganon P
J Med Assoc Thai; 2004 Aug; 87(8):887-90. PubMed ID: 15471291
[TBL] [Abstract][Full Text] [Related]
20. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J; Ebata R; Jibiki T; Yasukawa K; Saito H; Terai M
J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
